Compare Align Technology, Inc. (ALGN) vs Barclays PLC (BCS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Align Technology, Inc. vs Barclays PLC — how do they compare? Align Technology, Inc. trades at $175.63 (market cap $13.27B), while Barclays PLC trades at $26.77 (market cap $91.89B). The key difference: Barclays PLC is far larger — about 6.9× Align Technology, Inc.'s market cap, and Barclays PLC pays a 1.67% dividend while Align Technology, Inc. pays none. Which is the better fit depends on your goals.
| ALGN | BCS | |
|---|---|---|
Market Cap | $13.27B | $91.89B |
Sector | Health | Financials |
52-Week High | $207.19 | $28.41 |
52-Week Low | $124.88 | $18.31 |
Enterprise Value | $12.32B | — |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALGN trades at $185.22, up 0.38% today, with a bullish technical signal and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Revenue remains stable around $4.0B, supported by a 67.57% gross margin and positive cash flow trends. Recent news highlights global expansion and product innovation, including a new manufacturing facility in India.
Outlook is positive with a $220.75 consensus price target, though risks include regulatory scrutiny from the European Commission and competitive pressures. The stock's valuation at a P/E of 31.65 reflects growth expectations, but investors should monitor execution on international growth and demand stability in North America.
Barclays PLC (BCS) trades at $27.41, down 1.3% today but near its 52-week high of $28.43. The stock shows strong technical momentum with a bullish moving average signal, though RSI levels indicate potential overbought conditions. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $0.76 exceeding expectations, and maintains a healthy net income margin of 24.5%. Revenue growth has been steady, climbing to $29.14B in 2025.
The outlook remains positive given analyst consensus favoring Buy ratings (68%) and improving cash flow trends, but risks include ongoing securities litigation and sensitivity to interest rate changes. Valuation metrics like a P/E of 12.4 and P/B of 0.95 suggest potential upside if earnings momentum continues, though investors should weigh legal overhangs against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Align Technology, Inc.
Align is the leading manufacturer of clear dental aligners globally, having pioneered the technology with the introduction of its Invisalign branded aligners in 1998. Since then, Invisalign has become a household name, having treated over 10 million patients with malocclusion (misaligned teeth) through orthodontist and dentist-guided treatment plans. The company maintains dominant market share of clear aligners, despite the introduction of direct-to-consumer competitors upon the expiration of key patents that began in 2017. Align also manufactures intraoral scanners (iTero), used for orthodontic treatment and restorative dental procedures (digital models for crowns, veneers, and implants).
Read more on ALGN →About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →
